# Program 2: Experimental Therapeutics

> **NIH NIH P30** · UNIVERSITY OF IOWA · 2020 · $27,356

## Abstract

The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel
cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and
Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and
17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts
and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer-
reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for
non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have
authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing
therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36%
(n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter-
programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals
(impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate
based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel
Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel
approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer.
Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and
participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through
the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to
facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental
therapeutics pipeline.

## Key facts

- **NIH application ID:** 9914256
- **Project number:** 5P30CA086862-20
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Aliasger K Salem
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $27,356
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9914256

## Citation

> US National Institutes of Health, RePORTER application 9914256, Program 2: Experimental Therapeutics (5P30CA086862-20). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/9914256. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*